cinacalcet has been researched along with Hyperphosphatemia in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 12 (54.55) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Chon, Y; Drayer, D; Goodman, WG; Lai, J; Martin, KJ; Moore, C; Nemeth, EF; Ward, DT; Xu, J | 1 |
| Barreto, FC; Bucharles, SGE; Riella, MC | 1 |
| Hu, SL; Joshi, P; Kaplan, M; Lefkovitz, J; Michaud, DS | 1 |
| Bhargava, R; Brenchley, P; Hann, M; Hurst, H; Hutchison, AJ; Kalra, PA | 1 |
| Fukagawa, M; Kakuta, T; Komaba, H | 1 |
| Charytan, C; Yousaf, F | 1 |
| Adema, AY; de Borst, MH; Ter Wee, PM; Vervloet, MG | 1 |
| Fukagawa, M; Komaba, H; Tanaka, M | 1 |
| Fernández Giráldez, ED | 1 |
| Kalantar-Zadeh, K; Kovesdy, CP | 1 |
| Filson, J; Nguyen, TV | 1 |
| Yokoyama, K | 1 |
| Bos, WJ; Bouman, K; Braun, J; Brink, H; Carter, D; Frazão, JM; Graf, H; Macário, F; Maduell, F; Messa, P; Pontoriero, G; Reichel, H; Saha, H; Torregrosa, V; von Albertini, B; Wilkie, M; Yaqoob, M; Zani, VJ | 1 |
| Cannata-Andía, JB; Fernández-Martín, JL | 1 |
| Finch, JL; Lane, N; Nakamura, H; Shahnazari, M; Slatopolsky, E; Tokumoto, M; Yao, W | 1 |
| Goltzman, D | 1 |
| Ahlenstiel, T; Ariceta, G; Bak, M; Bakkaloglu, SA; Borzych, D; Chua, A; Ha, IS; Hari, P; Klaus, G; Lipka, M; Lopez, L; Ozaltin, F; Printza, N; Rees, L; Schaefer, F; Spizzirri, AP; Valles, PG; Vogel, A; Warady, BA; Yap, HK; Zambrano, P | 1 |
| Abreu, C; Castro, JC; Díez, JJ; Iglesias, P | 1 |
| Youssef, D | 1 |
| Tominaga, Y | 1 |
| Akizawa, T; Kinugasa, E; Koiwa, F; Ogata, H | 1 |
| Block, GA; Bushinsky, DA; Chertow, GM; Chi, EM; Sugihara, J; Turner, SA; Zeig, S | 1 |
8 review(s) available for cinacalcet and Hyperphosphatemia
| Article | Year |
|---|---|
Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.
Topics: Bone and Bones; Calcimimetic Agents; Chelating Agents; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Medication Adherence; Naphthalenes; Receptors, Calcitriol; Renal Insufficiency, Chronic; Vitamin D | 2013 |
Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism.
Topics: Bone Density; Cardiovascular Diseases; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Naphthalenes; Practice Guidelines as Topic | 2014 |
Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
Topics: Calcium; Calcium, Dietary; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Diet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Naphthalenes; Phosphorus; Phosphorus, Dietary; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2014 |
Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Topics: Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Japan; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Vitamin D | 2008 |
[Clinical advances in vascular calcification].
Topics: Aged; Animals; Atherosclerosis; Calcinosis; Chronic Disease; Cinacalcet; Coronary Artery Disease; Diabetes Complications; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Diseases; Mice; Mice, Knockout; Multicenter Studies as Topic; Naphthalenes; Polyamines; Randomized Controlled Trials as Topic; Renal Artery; Sevelamer; Tomography, Spiral Computed; Tomography, X-Ray Computed; Vascular Diseases | 2008 |
[Chronic kidney disease (CKD) and bone. Vascular calcification in CKD].
Topics: Animals; Calcinosis; Calcium; Chelating Agents; Chronic Disease; Cinacalcet; Diphosphonates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperphosphatemia; Kidney Diseases; Naphthalenes; Phosphates; Polyamines; Prognosis; Randomized Controlled Trials as Topic; Rats; Sevelamer; Vascular Diseases | 2009 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Parathyroidectomy for secondary hyperparathyroidism].
Topics: Chronic Disease; Cinacalcet; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Japan; Kidney Diseases; Naphthalenes; Parathyroidectomy; Practice Guidelines as Topic | 2012 |
CKD-MBD: impact on management of kidney disease.
Topics: Aniline Compounds; Bone Diseases, Metabolic; Calcium Metabolism Disorders; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Naphthalenes; Phenethylamines; Polyamines; Propylamines; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency; Vitamins | 2007 |
3 trial(s) available for cinacalcet and Hyperphosphatemia
| Article | Year |
|---|---|
A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis.
Topics: Aged; Cardiovascular Diseases; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Female; Follow-Up Studies; Humans; Hydroxycholecalciferols; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Patient Acceptance of Health Care; Patient Dropouts; Phosphates; Phosphorus, Dietary; Renal Dialysis; Sepsis; Sevelamer | 2019 |
Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
Topics: Adult; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Male; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Vitamin D | 2009 |
Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
Topics: Adult; Aged; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Severity of Illness Index; Sterols; Treatment Outcome; Vitamin D | 2008 |
11 other study(ies) available for cinacalcet and Hyperphosphatemia
| Article | Year |
|---|---|
Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia.
Topics: Aged; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Male; Middle Aged; Parathyroid Hormone; Peptides; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies | 2022 |
The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Topics: Adult; Aged; Alkaline Phosphatase; Calcimimetic Agents; Calcium; Cinacalcet; Female; Follow-Up Studies; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Hypocalcemia; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Retrospective Studies; Treatment Outcome; Vitamin D | 2019 |
Vitamin D and cinacalcet are associated with increased survival in peritoneal dialysis but not with residual renal function preservation
.
Topics: Cinacalcet; Humans; Hyperphosphatemia; Peritoneal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Vitamin D | 2018 |
Is it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet story.
Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Hypocalcemia; Kidney Failure, Chronic; Naphthalenes; Phosphorus | 2009 |
Caring for chronic kidney disease patients: focus on mineral and bone disorders.
Topics: Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diet Therapy; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Metabolic Diseases; Middle Aged; Naphthalenes; Parathyroid Hormone; Pharmaceutical Services; Phosphorus; Receptors, Calcium-Sensing; Renal Dialysis; Vitamin D | 2009 |
Mineral metabolism: Should cinacalcet be used in patients who are not on dialysis?
Topics: Cinacalcet; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Hypocalcemia; Kidney Failure, Chronic; Naphthalenes; Renal Dialysis | 2009 |
Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.
Topics: Animals; Biomarkers; Bone Resorption; Calcitriol; Calcium; Cinacalcet; Creatinine; Disease Models, Animal; Ergocalciferols; Female; Fibroblast Growth Factors; Hyperparathyroidism; Hyperphosphatemia; Hypocalcemia; Naphthalenes; Nephrectomy; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic; Severity of Illness Index; Tibia; Uremia | 2010 |
Do calcimimetics directly alter bone remodeling?
Topics: Animals; Biomarkers; Bone Remodeling; Bone Resorption; Calcitriol; Cinacalcet; Ergocalciferols; Fibroblast Growth Factors; Humans; Hyperparathyroidism; Hyperphosphatemia; Hypocalcemia; Naphthalenes; Parathyroid Hormone; Rats; Renal Insufficiency, Chronic; Severity of Illness Index; Tibia; Treatment Outcome; Uremia | 2010 |
The bone and mineral disorder of children undergoing chronic peritoneal dialysis.
Topics: Adolescent; Calcium; Child; Child, Preschool; Cinacalcet; Europe; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Hypocalcemia; Infant; Kidney Failure, Chronic; Latin America; Male; Naphthalenes; North America; Parathyroid Hormone; Peritoneal Dialysis; Phosphate-Binding Proteins; Phosphorus; Prospective Studies; Registries; Vitamin D; Young Adult | 2010 |
[Long-term combined treatment with cinacalcet and bisphosphonates in persistent primary hyperparathyroidism after surgery].
Topics: Alendronate; Bone Density Conservation Agents; Cinacalcet; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Hypercalciuria; Hyperparathyroidism, Primary; Hyperphosphatemia; Middle Aged; Naphthalenes; Osteoporosis; Postoperative Complications | 2012 |
Short-term use of cinacalcet in children on regular hemodialysis.
Topics: Adolescent; Calcimimetic Agents; Child; Cinacalcet; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Male; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic | 2012 |